Find Academic Supervisors

• Immunology
• Systems Biology
• Genomics
• +4 more

Dr. Masahiro Ono is a Reader in Immunology at Imperial College London's Department of Life Sciences, within the Faculty of Natural Sciences. He leads research on T-cell regulation, focusing on autoimmunity, infections, and cancer. His lab pioneered the Tocky system, using Fluorescent Timer proteins to study T-cell activity dynamics in vivo. Dr. Ono holds affiliations with the CRUK Convergence Science Centre, Infection and Immunity, and Integrative Systems Biology. His academic journey includes an MD from Kyoto University (1993-1999) and a PhD in regulatory T cells (2002-2006). He was awarded a HFSP Fellowship (2009) and BBSRC David Phillips Fellowship (2012), establishing his UCL lab before joining Imperial in 2015. Research Interests : Dr. Ono's work bridges immunology, genomics, and systems biology. His lab explores T-cell activation mechanisms, tumor immunology, and bioinformatics tools for single-cell analysis. Key innovations include the Tocky system for real-time cell kinetics tracking and integrative approaches like GatingTree for cytometry data analysis. Awards : HFSP Fellowship (2009) BBSRC David Phillips Fellowship (2012) Grants & Advising : Dr. Ono's grants have supported projects on viral latency, tumor microenvironment modulation, and immune checkpoint therapies. His lab actively collaborates on translational research, though specific grant details are not listed here. Labs & Teams : His lab at Imperial focuses on Tocky-based technologies and interdisciplinary convergence science through the CRUK Centre. Collaborations span virology, oncology, and bioengineering to address unmet clinical needs in immunotherapy.

Anne Ferguson-SmithView profile

Professor

• Genomic Imprinting
• Epigenetics
• Developmental Genetics
• +3 more

Professor Anne Ferguson-Smith is a leading mammalian developmental geneticist and epigeneticist at the University of Cambridge, holding the Arthur Balfour Professorship of Genetics. As Pro-Vice-Chancellor for Research, she oversees the university's research strategy while maintaining her laboratory's focus on genomic imprinting and epigenetic inheritance . Her work bridges experimental and computational approaches through affiliations with the Cambridge Stem Cell Institute, Cambridge Neuroscience, and the Centre for Trophoblast Research. Research in her lab investigates epigenetic mechanisms in developmental processes , particularly through the lens of Dlk1-Dio3 imprinted domain studies. Current themes include: Stem cell epigenetic programming Environmental modulation of epigenetic states Role of repetitive elements in genomic regulation Her group integrates mouse and zebrafish models with high-throughput genomics and mathematical modeling . Key collaborations include: Wellcome Trust UKRI Medical Research Council BBSRC NIH Scientific honors include: Elected EMBO Member (2006) Academy of Medical Sciences (2012) Fellow of the Royal Society (2017) Commander of the Order of the British Empire (CBE) The lab maintains family-friendly research practices and actively participates in interdisciplinary collaborations across Cambridge and internationally.

Nathanael S. GrayView profile

Professor

• Kinase inhibitor design
• Targeted protein degradation
• Cancer drug discovery
• +6 more

Nathanael S. Gray , Krishnan-Shah Family Professor at Stanford University , holds concurrent appointments in the Stanford Cancer Institute , Chem-H , and Innovative Medicines Accelerator . His research integrates synthetic chemistry, protein biochemistry, and cancer biology to develop novel therapeutic strategies. PhD in Organic Chemistry (1999) and BS with Highest Honor (1995) from UC Berkeley Director of Biological Chemistry at GNF (2000-2006) Faculty at Dana-Farber/Harvard (2006-2021) Research focuses on kinase inhibitors (BCR-ABL, ALK, EGFR mutants), molecular glue degraders (CDK12/13, BRD4, CK1α), and epigenetic rewiring (KAT-TCIPs for BCL6-driven cancers). Recent work explores antimalarial kinase inhibitors and immunomodulatory degraders for solid and hematologic malignancies. Publication trends show expertise in targeted protein degradation (15/15 articles), kinase pharmacology (12/15), oncogenic driver targeting (9/15), and parasitic disease (4/15). Scientific awards include National Science Foundation Career (2007) Paul Marks Prize (2019) Hope Funds for Cancer Research (2023) Advises 30+ doctoral students and postdocs, with grants spanning oncology , infectious disease , and immunology . Leads drug development programs for KRAS, HER3, and BCL6 targets.

Adele MurrellView profile

Professor

• Epigenetics
• Genomic Imprinting
• DNA Methylation
• +6 more

Professor Adele Murrell is a Professor of Epigenetics in the Department of Life Sciences at the University of Bath's Faculty of Science. She serves as Co-Director of the Centre for Therapeutic Innovation and is affiliated with both the Centre for Mathematical Biology and the Centre for Bioengineering & Biomedical Technologies (CBio). She is currently accepting doctoral students and maintains an active research program with multiple ongoing projects. Her research focuses on understanding how cells establish and maintain their specific identities through epigenetic mechanisms. Her work centers on epigenetic barriers and cell identity, genomic imprinting as a model epigenetic system, long-range epigenetic silencing in cancer, and epigenetic reprogramming during metastasis. She investigates how higher-order chromatin structure and epigenetic modifications shape the genome within the nucleus to constitute cell identity and provide memory of developmental origins. Her current work examines colon cancer and liver metastasis, focusing on changes in DNA methylation and its demethylation intermediates such as 5-hydroxymethylcytosine. Analysis of Professor Murrell's recent publications reveals a strong focus on DNA hydroxymethylation patterns in cancer progression, particularly in colorectal cancer metastasis. Her work bridges molecular epigenetics with clinical applications, exploring how epigenetic changes during metastasis could be targeted to prevent cancer spread. She has developed novel techniques for detecting epigenetic modifications and has made significant contributions to understanding allele-specific chromatin domains and genomic imprinting mechanisms. Professor Murrell leads multiple research projects including 'Two stages of genome wide 5-hydroxymethylcytosine (5hmC) reprogramming during colorectal carcinogenesis and liver metastasis' funded by the MRC until February 2024, and 'Modelling the fits and starts of how genes burst into expression' funded by The Leverhulme Trust until June 2024. She was also a Co-Investigator on the 'Multi User High-Content Confocal Microscope' project funded by the Biotechnology and Biological Sciences Research Council. Her laboratory work connects with UN Sustainable Development Goals, particularly those related to health and well-being. Her fingerprint analysis shows strong activity in Epigenetics (100%), DNA Methylation (94%), Allele research (73%), Methylation studies (69%), Genomic Imprinting (60%), CTCF research (56%), Promoter Region analysis (44%), and Differentially Methylated Regions (34%).

Dean TantinView profile

Professor

• Gene regulation in T cells
• T cell memory and autoimmunity
• Stem cell biology
• +4 more

Dean Tantin is a Professor of Microbiology and Immunology at the University of Utah School of Medicine, where his research delves into gene regulation in T cells, stem cells, and cancer. His lab investigates how transcription factors like Oct1, Oct4, and OCA-B control stem-like properties in cells, impacting immunological memory, autoimmunity, and cancer progression. Education: B.S. – University of California, San Diego Ph.D. – University of California, Los Angeles Research Interests: Dr. Tantin’s work centers on understanding how transcription factors regulate cell fate decisions, particularly in T cells and stem cells. His lab explores the roles of Oct1 and Oct4 in pluripotency and differentiation, the function of OCA-B in T cell memory and autoimmunity, and the therapeutic potential of targeting these factors in diseases like multiple sclerosis and type 1 diabetes. A major focus is on how these transcription factors control gene expression programs that endow cells with longevity, self-renewal, and rapid response capabilities. Article Trends: Recent publications highlight a strong emphasis on transcriptional regulation in immune cells, particularly CD4+ T cells, and stem cells. Studies explore how OCA-B and Oct factors influence T cell memory formation, autoimmune responses, and cancer development. The work bridges molecular mechanisms with translational applications, including potential drug targets for autoimmune diseases and cancer. Laboratory and Team: Dr. Tantin leads an active research group at the University of Utah, supported by training grants and core facilities. His lab employs molecular biology, genomics, and in vivo models to dissect transcriptional networks. While specific student names are not listed, his mentorship is evident through his involvement in bioscience PhD programs and collaborative projects.

Hilary Ann CollerView profile

Professor

• Cellular Quiescence
• Cancer Biology
• Metabolism
• +4 more

Hilary Ann Coller is a Professor at the University of California, Los Angeles (UCLA), jointly appointed in the Department of Molecular, Cell and Developmental Biology and the Department of Biological Chemistry within the College of Letters and Science. She leads a research laboratory focusing on cellular quiescence, metabolism, and their implications in cancer and disease progression. Her research integrates molecular biology, epigenetics, and systems approaches to study: Transcriptional and epigenetic control of quiescence Metabolic adaptations in tumor microenvironments RNA biology and gene regulation networks Development of biomedical technologies (e.g., biosensors) Recent publications (2022–2025) highlight trends in: Cellular quiescence mechanisms and transcription factor dynamics Cancer epigenetics and metabolic reprogramming Innovative tools for metabolomics and drug monitoring Educational research on remote STEM training programs She directs multiple NIH-funded projects, including R01CA221296 (stromal autophagy in melanoma) and R01GM086465 (microRNA mechanisms). Her lab mentors graduate students and postdocs, and she co-leads UCLA’s Bruins-in-Genomics summer initiative for undergraduate computational biology training.

Pilar BlancafortView profile

Associate Professor

• Cancer Biology
• Epigenetics
• Genome Engineering
• +7 more

Pilar Blancafort is an Associate Professor at The University of Western Australia (UWA), holding positions in the School of Human Sciences and UWA Medical School. She is affiliated with the UWA Centre for Medical Research and collaborates with the Harry Perkins Institute of Medical Research. Her research focuses on epigenetic manipulation in cancer models, particularly breast and ovarian cancers, leveraging CRISPR/Cas9 and genome engineering technologies to develop precision medicine tools. She has co-led projects such as the Lionheart FX Automated High-Content Microscope initiative and actively investigates therapeutic reprogramming of cellular signaling pathways to improve cancer treatment outcomes. Blancafort’s research expertise includes genome engineering, cancer epigenetics, and women’s cancers. She collaborates internationally and has contributed to over 70 publications, 14 datasets, and 43 grants. Her work aligns with UN Sustainable Development Goals, emphasizing global health and innovation in medical research. Key areas of exploration involve reactivating tumor suppressors, silencing oncogenic drivers, and enhancing immune responses through CRISPR-based systems. Her studies on the PI3K-AKT-mTOR pathway and novel oncogenes further underscore her commitment to advancing targeted therapies. Blancafort has supervised 11 students and leads multiple grants, including projects on metastatic breast cancer therapies and ovarian cancer reprogramming. Her lab at the UWA Centre for Medical Research explores translational strategies for epigenome editing in cancer, with a focus on clinical applicability. Recent work highlights lipid nanoparticle delivery systems for CRISPR/dCas9 and synthetic epigenetic approaches to reverse mesenchymal-epithelial transitions in breast cancer.

Susanne KooistraView profile

Research Professor

• Neuroscience
• Molecular Biology
• Neuroinflammation
• +6 more

Dr. Susanne Kooistra is a Research Professor in the Faculty of Medical Sciences at the University of Groningen, affiliated with the University Medical Center Groningen (UMCG). She leads the Senescence, Stem Cells, and Inflammation (SSI) research group, focusing on neuroinflammation, microglial biology, and epigenetic regulation in neurological disorders. Her work spans multiple sclerosis, Alzheimer’s disease, and developmental neurobiology, emphasizing the role of microglia in disease progression and repair mechanisms. Her research integrates transcriptomic and epigenetic approaches to study immune responses in the central nervous system, particularly in contexts of aging, injury, and developmental stressors. Collaborations with institutions like the UMCG and international teams have advanced insights into microglial heterogeneity, myelin repair, and the impact of environmental factors on neurodevelopmental outcomes. Dr. Kooistra’s publications highlight contributions to understanding microglial function in demyelination, stress-induced immune modulation, and epigenetic memory in neuroinflammation. Her work has been recognized through high-impact journals and international peer-reviewed contributions, with a focus on translating basic discoveries into clinical insights for neurodegenerative diseases.

Khashayarsha KhazaieView profile

Professor

• Cancer Immunology
• Inflammation
• Regulatory T Cells
• +12 more

Khashayarsha Khazaie, Ph.D., is a Professor of Immunology at Mayo Clinic in Phoenix, Arizona, with a primary appointment as a Consultant in the Department of Immunology and a joint appointment in Cancer Biology, Department of Research. He leads a research laboratory focused on cancer immunology, inflammation, and the tumor-microbiota-immune axis, with emphasis on gastrointestinal and gynecological malignancies. Education: Ph.D. in Genetics/Senescence, MRC, National Institute for Medical Research Doctor of Science, University of Paris V, René Descartes BSc (Hons) in Chemistry, Biology, Physics, University of Surrey Postdoctoral Research, CNRS; EMBL; National Institute for Medical Research Research Interests: Dr. Khazaie’s lab investigates regulatory T cells (Tregs), mast cells, circadian rhythms, fibrosis, and microbial-based cancer vaccines. His work explores how immune suppression and chronic inflammation promote tumor growth, particularly in colorectal and endometrial cancers. Key areas include Treg plasticity, epigenetic reprogramming, microbiota-driven carcinogenesis, and the immunology of metastasis. Recent Research Trends: His most recent publications highlight the role of circadian disruption in colon cancer, the therapeutic potential of biomaterial-enhanced Treg immunotherapy, and the use of single-cell and spatial-omics to dissect immune-related diseases. His studies integrate molecular, cellular, and systems-level approaches to understand immune dysregulation in cancer and chronic inflammation. Scientific Leadership: Director, Federation of Clinical Immunology Societies, Mayo Clinic Center of Excellence (2018–present) Associate Editor, Journal for ImmunoTherapy of Cancer (2013–present) Editorial Board, Cancer Immunology Research (2012–present) Associate Editor, Tumor Immunity, Frontiers in Immunology and Oncology (2011–present) Visiting Professor, University of Regensburg (2016); Université Paris-Est Créteil (2016) Grants and Advising: Dr. Khazaie has led multiple NIH-funded projects, including studies on Parvimonas micra-induced carcinogenesis, β-catenin in Treg expansion, and circadian disruption in colon cancer. He mentors researchers and contributes to the education of future physicians and scientists in immunology and cancer biology. His lab collaborates with Biomed Valley Discoveries and MD Anderson on clinical trials of bacterial vaccines for metastatic cancer. Laboratory and Collaborations: His laboratory operates at the interface of basic and translational science, using mouse models, clinical specimens, and multi-omics technologies. He is deeply involved in collaborative research networks, particularly in cancer immunology and microbiota studies.

• Biomedical Engineering
• Nanotechnology
• Tumor Therapy
• +4 more

Liu Hongmei is a Researcher and Master's Supervisor at Southern University of Science and Technology's Department of Biomedical Engineering. Holding a Ph.D. from the Chinese Academy of Sciences, she specializes in micro-nano robotics and tissue engineering for tumor therapy, with over 66 publications and 12 patents. Her work bridges biomedical engineering and nanotechnology for precision cancer treatments. B.S., Biological Sciences, Harbin Normal University (2005) M.S., Botany, Northeast Agricultural University (2008) Ph.D., Biochemical Engineering, Chinese Academy of Sciences (2015) Her research focuses on biomaterials engineering , nanoparticle drug delivery , and microenvironment-responsive hydrogels . Key areas include glioma therapy, traumatic brain injury recovery, and intervertebral disc degeneration treatments. Recent work explores pH/ROS/inflammation-triggered hydrogels and bioengineered bacteria for disease modulation. Article trends show a strong emphasis on nanoparticle design (2014-2025) for glioma, hydrogel development (2017-2025) for tissue repair, and biomimetic material synthesis (2023-2025) inspired by spider silk and meniscus structures. Sub-fields span pyroptosis inhibition, epigenetic reprogramming, and microbiome engineering. Jiangsu Science and Technology Award (2020) Jiangsu Medical Science and Technology Award (2020) Jiangsu Educational Science Research Award (2021) Chinese Medical Doctor Association's Outstanding Young Scientist (2018) Liu has supervised numerous projects including National Natural Science Foundation of China grants, Jiangsu Province Key R&D Program funding, and Shenzhen City General Projects. She holds 12 Chinese invention patents and collaborates with institutions like the UNESCO Centre for Higher Education Innovation.

Kathryn E. WellenView profile

Professor

• Cellular Metabolism
• Cancer Biology
• Diabetes
• +6 more

Kathryn E. Wellen is a Professor of Cancer Biology at the University of Pennsylvania Perelman School of Medicine. She holds dual affiliations as an Associate Investigator at the Abramson Family Cancer Research Institute and an Investigator at the Penn Epigenetics Institute. Her research focuses on the intersection of cellular metabolism, epigenetic regulation, and cancer progression, with a particular emphasis on nutrient-sensitive pathways like acetylation and glycosylation. Education: B.S. in Biological Psychology, College of William and Mary (2000) Ph.D. in Biological Sciences (Genetics & Complex Diseases), Harvard University School of Public Health (2006) Dr. Wellen's work investigates how metabolic pathways influence gene expression and signaling networks in diseases such as cancer and diabetes. Key mechanisms include ATP-citrate lyase (ACLY)-dependent histone acetylation and hexosamine pathway regulation of N-linked glycans, both of which impact tumor growth and cellular interactions with their environment. Her recent publications highlight the role of acetyl-CoA metabolism in cancer (2023), obesity-induced immunosuppression via PD-1 upregulation (2024), and metabolic-epigenetic interactions in glioblastoma resistance (2023). She also explores fructose metabolism in liver disease (2020) and lactate's role in macrophage polarization (2021). Dr. Wellen serves as Vice Chair of the Department of Cancer Biology and mentors graduate students and postdoctoral researchers. Her lab team includes Sydney Campbell , Luke Izzo , Hayley Affronti , Sully Fernandez , Alessandro Carrer , Sophie Trefely , and Steven Zhao .

Yi ZhangView profile

Professor

• Epigenetics
• Chromatin Biology
• Gene Regulation
• +4 more

Yi Zhang serves as the Fred Rosen Professor of Pediatrics at Boston Children's Hospital and Professor of Genetics at Harvard Medical School, leading pioneering research in epigenetic regulation and disease mechanisms. His academic journey includes: BS from China Agriculture University (1984) PhD from Florida State University (1995) Postdoctoral training at Robert Wood Johnson Medical School of UMDNJ Dr. Zhang's work centers on epigenetic modifications , particularly DNA methylation and histone dynamics, investigating their critical roles in: Chromatin structure and gene expression control Embryonic development and cell lineage specification Stem cell pluripotency and reprogramming Disease pathogenesis including cancer, diabetes, and neurological disorders His lab's identification of key enzymes (Tet family, EZH2, JmjC proteins) established foundational knowledge for epigenetic drug development, directly enabling Epizyme's creation and FDA-approved therapy tazemetostat. Publications consistently focus on epigenetic enzyme mechanisms, with recent work examining DNA methyltransferases' developmental roles and advancing single-cell epigenomic analysis techniques. Major recognitions include: National Academy of Medicine election (2023) Howard Hughes Medical Institute Investigator (2005) Gertrude B. Elion Cancer Research Award Kimmel Scholar Award Chinese Biological Investigators’ Society Senior Investigator Award While specific grant details and student mentorship records aren't provided in source materials, his lab maintains significant research operations through institutional affiliations. The Zhang Laboratory employs cutting-edge methodologies including single-cell live imaging, stem cell differentiation systems, and advanced mouse genetics to dissect epigenetic mechanisms in disease contexts.

Guo-Cheng YuanView profile

Professor

• Genomics
• Epigenetics
• Gene Expression
• +4 more

Guo-Cheng Yuan is a Senior Faculty member in the Department of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai. His research focuses on genomics, epigenetics, and computational biology , with particular emphasis on single-cell analysis, chromatin regulation, and cancer immunology. Institution: Icahn School of Medicine at Mount Sinai School: Graduate School of Biomedical Sciences Department: Genetics and Genomic Sciences Research Interests Dr. Yuan's work spans multiple domains including: Single-cell RNA sequencing applications in brain development and cancer Chromatin structure analysis in differentiation processes Spatial transcriptomics for tissue microenvironment characterization Computational methods for multiomic data integration Enhancer-promoter interaction dynamics Development of robust bioinformatics pipelines Scientific Trends Analysis His recent publications (2021-2025) demonstrate a focus on single-cell and spatial omics methodologies applied to diverse biological contexts ranging from cancer immunology to neurodevelopment . Notable trends include: Development of trajectory analysis algorithms Multiomic integration for regulatory network mapping Epigenetic mechanisms in cell differentiation Computational approaches for data robustness Three-dimensional genome organization studies Applications in both developmental biology and oncology

Rodney J. TaylorView profile

Professor

• Head and Neck Surgical Oncology
• Rhinology and Sinus Disease
• Endocrine Surgery
• +7 more

Rodney J. Taylor is a Professor and Chair of the Department of Otorhinolaryngology-Head & Neck Surgery at the University of Maryland School of Medicine. With clinical expertise in head and neck cancer management, skull base surgery, and endocrine surgery, he has led national-recognized research initiatives since joining the faculty in 2001. As Chief of Otolaryngology at the Baltimore Veteran’s Administration Medical Center, he combines clinical excellence with scientific innovation. Education : MD from Harvard Medical School (1995), MPH from University of Michigan School of Public Health (1999) Training : Residency in Otolaryngology-Head & Neck Surgery at University of Michigan (1995-2001) Dr. Taylor's research focuses on improving head and neck cancer survival through immune-cytotoxicity studies, SCCHN cell line analysis, xenograft models, and clinical trials. His collaborations with Dr. Zalzman's lab explore cancer stem cell immortality mechanisms and regenerative medicine advancements. Current research also investigates NK cell FcγRIIIa polymorphisms for personalized antibody therapy. Scientific achievements include developing the Neck Dissection Impairment Index and recognition as a top otolaryngologist. His lab secures funding from NIH, DOD, and philanthropic sources like the Orokawa Foundation and Weitzman family. Research trends emphasize translational oncology, immunotherapy, and stem cell applications in head and neck diseases. Scientific Awards : Ranked among 'America’s Top Otolaryngologists'

• Melanoma Biology
• Cancer Immunology
• Tumor Microenvironment
• +4 more

Marcus Bosenberg, MD, PhD, is the Anthony N. Brady Professor of Dermatology, Pathology and Immunobiology at Yale School of Medicine. He serves as Director of the Yale SPORE in Skin Cancer, Director of the Yale Center for Immuno-Oncology, Co-Leader of the Cancer Immunology Program at Yale Cancer Center, and Director of the Center for Precision Cancer Modeling. As a practicing dermatopathologist at Yale Medicine, he specializes in diagnosing skin cancers and inflammatory disorders. Education & Training: BA, Cornell University (1986) PhD, Cornell University Medical College (1993) MD, Cornell University Medical College (1994) Residency: Brigham & Women's Hospital Fellowships: Harvard Medical School Dermatopathology, Dana-Farber Cancer Institute Research Focus: Dr. Bosenberg's laboratory investigates melanoma biology, anti-cancer immune responses, metastasis mechanisms, and therapeutic development. His team pioneered mouse models for melanoma progression and therapy testing, with strong emphases on tumor microenvironment interactions, epigenetic regulation of immunity, and precision cancer modeling. Key research areas include BRAF/MEK signaling pathways, DNA methylation in immunotherapy resistance, and nanoparticle-based drug delivery systems. Publication Trends: His recent articles (2023-2025) demonstrate a strong focus on melanoma immunotherapy resistance mechanisms, tumor microenvironment modulation, and diagnostic innovations. Epigenetic regulation (e.g., DNA methylation, Setdb1) emerges as a recurrent theme, alongside novel approaches to enhance T-cell responses and overcome immune evasion. Nanotechnology applications for targeted drug delivery and advanced molecular diagnostics feature prominently in his translational work. Awards: Yale School of Medicine Basic Science Research Prize (2022) Mentoring & Leadership: Dr. Bosenberg mentors undergraduate, graduate, and medical students along with postdoctoral fellows. He directs multiple research centers and leads the Yale SPORE in Skin Cancer, focusing on translational melanoma research. His laboratory develops patient-derived tumor models for renal cell carcinoma and melanoma studies.